Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

VIR BIOTECHNOLOGY, INC.

(VIR)
  Report
Delayed Nasdaq  -  04:00 2022-11-29 pm EST
27.26 USD   +1.15%
11/17Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500
AQ
11/16Vir Biotechnology Ranked the Fastest-Growing Company in North America on theá2022 Deloitte Technology Fast 500™
GL
11/16Vir Biotechnology Ranked the Fastest-Growing Company in North America on theá2022 Deloitte Technology Fast 500™
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Days
:
Hours
:
Minutes
:
Seconds

Vir Biotechnology Doses First Patients in Phase 2 SOLSTICE Trial Evaluating Chronic Hepatitis D Virus Infection

09/22/2022 | 02:32pm EST


ę MT Newswires 2022
All news about VIR BIOTECHNOLOGY, INC.
11/17Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2022 Deloi..
AQ
11/16Vir Biotechnology Ranked the Fastest-Growing Company in North America on theá2022 Deloi..
GL
11/16Vir Biotechnology Ranked the Fastest-Growing Company in North America on theá2022 Deloi..
AQ
11/15Britain's NICE recommends against NHS use of 5 COVID treatments as not cost-effective
RE
11/09Insider Sell: Vir Biotechnology
MT
11/07Vir Biotechnology Says Preliminary Phase 2 Data Supports Potential of Hepatitis B Drug ..
MT
11/06Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 andáVIR-3434 ..
AQ
11/06Vir Biotechnology, Inc. Presents New Data Evaluating the Potential for Vir-2218 and Vir..
CI
11/06Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 andáVIR-3434 ..
GL
11/04Sector Update: Health Care Stocks Higher Amid Late Markets Advance
MT
More news
Analyst Recommendations on VIR BIOTECHNOLOGY, INC.
More recommendations
Financials (USD)
Sales 2022 1 717 M - -
Net income 2022 597 M - -
Net cash 2022 1 331 M - -
P/E ratio 2022 6,17x
Yield 2022 -
Capitalization 3 587 M 3 587 M -
EV / Sales 2022 1,31x
EV / Sales 2023 7,30x
Nbr of Employees 444
Free-Float 86,5%
Chart VIR BIOTECHNOLOGY, INC.
Duration : Period :
Vir Biotechnology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIR BIOTECHNOLOGY, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 26,95 $
Average target price 47,89 $
Spread / Average Target 77,7%
EPS Revisions
Managers and Directors
George A. Scangos President, Chief Executive Officer & Director
Howard Horn CFO, Secretary & Chief Accounting Officer
Vicki L. Sato Non-Executive Chairman
Phil Pang Chief Medical Officer
Aine M. Hanly Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
VIR BIOTECHNOLOGY, INC.-35.63%3 587
MODERNA, INC.-30.95%67 378
IQVIA HOLDINGS INC.-23.99%39 832
LONZA GROUP AG-34.32%39 180
ALNYLAM PHARMACEUTICALS, INC.23.36%25 738
SEAGEN INC.-21.59%22 506